Bausch + Lomb BLCO Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Total revenues by Business | ||||||
| Pharmaceuticals | $1.13B+14.6% | $1.08B+11.6% | $1.03B+6.8% | $997M+20.1% | $982M+36.6% | |
| Surgical | $908M+5.6% | $894M+6.0% | $876M+7.4% | $867M+9.1% | $860M+10.1% | |
| Vision Care | $2.98B+7.9% | $2.92B+6.7% | $2.87B+7.1% | $2.82B+6.6% | $2.76B+6.5% | |
| Operating Income (Loss) by Business | ||||||
| Pharmaceuticals | $313M+46.3% | $258M+0.8% | $180M-34.3% | $173M-32.9% | $214M-13.7% | |
| Surgical | $34M+30.8% | $18M-59.1% | $19M-61.2% | $24M-46.7% | $26M-48.0% | |
| Vision Care | $875M+8.6% | $849M+5.1% | $839M+10.8% | $823M+11.5% | $806M+13.0% | |
| Selling, general and administrative (Note 4) by Business | ||||||
| Pharmaceuticals | $557M-3.0% | $572M+5.3% | $597M+28.2% | $602M+47.2% | $574M+57.9% | |
| Surgical | $298M+8.8% | $298M+12.5% | $288M+12.1% | $280M+9.8% | $274M+9.6% | |
| Vision Care | $919M+4.0% | $912M+3.4% | $897M+1.7% | $891M+2.3% | $884M+4.9% | |
| R&D by Business | ||||||
| Pharmaceuticals | $66M+83.3% | $53M+60.6% | $47M+74.1% | $39M+56.0% | $36M+71.4% | |
| Surgical | $45M+2.3% | $43M+2.4% | $47M+24.5% | $46M+26.0% | $44M+24.8% | |
| Vision Care | $50M+22.0% | $48M+4.3% | $44M-16.6% | $41M-28.7% | $41M-35.2% | |
| Goodwill, Foreign Currency Translation, Gain (Loss) by Business | ||||||
| Pharmaceuticals | -$59M-2,850% | -$105M-314% | -$48M-17.1% | -$78M-657% | -$2M— | |
| Surgical | -$5M-150% | -$13M-360% | -$5M+16.7% | -$9M— | -$2M— | |
| Goodwill by Business | ||||||
| Pharmaceuticals | $2.97B+10.2% | $2.91B+8.3% | $2.81B+2.7% | $2.77B+2.7% | $2.69B+0.1% | |
| Surgical | $1.64B+20.5% | $1.54B+15.7% | $1.43B+9.5% | $1.4B+7.8% | $1.36B+4.9% | |
| Vision Care | $14.22B+0.4% | $14.2B+0.2% | $14.17B-0.2% | $14.17B-0.1% | $14.16B-0.3% | |
| Total revenues by Product | ||||||
| Branded and Other Generics | $237M-11.9% | $242M-13.9% | $240M-8.7% | $251M-5.3% | $269M+4.7% | |
| Devices | $1.95B+7.1% | $1.92B+6.8% | $1.88B+7.5% | $1.85B+8.6% | $1.82B+9.4% | |
| OTC | $1.87B+7.6% | $1.84B+6.4% | $1.81B+6.9% | $1.77B+5.6% | $1.74B+5.1% | |
| Cost of goods sold (excluding amortization and impairments of intangible assets) and Cost of other revenues by Product | ||||||
| Other revenues | $5M+25.0% | $5M+25.0% | $6M+200% | $5M+66.7% | $4M+100% | |
| Product sales | $2.05B+6.2% | $2.05B+9.5% | $2.01B+9.9% | $1.97B+12.0% | $1.93B+13.8% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Bausch + Lomb break its business down?
- Bausch + Lomb (BLCO) reports total revenues by business across 3 parts — Pharmaceuticals, Surgical and Vision Care. Each is extracted from the segment footnotes and tracked over time.
- Where does Bausch + Lomb's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Bausch + Lomb's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.